Tranexamic acid in spontaneous intracerebral hemorrhage: an updated systematic review and meta-analysis of randomized controlled trials
Open Access
- 3 March 2026
- journal article
- research article
- Published by Taylor & Francis in Annals of Medicine
- Vol. 58 (1) , 2635208
Abstract
Tranexamic acid (TXA) is a well-established antifibrinolytic medication in the general population. However, its efficacy and safety for patients with spontaneous intracerebral hemorrhage (ICH) remain inconclusive. Consequently, we conducted a systematic review and meta-analysis to assess the effectiveness and safety of TXA for spontaneous ICH. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) following established methodological standards. Our search encompassed eight electronic databases from inception to April 25, 2024. The primary outcome was a reduction in all-cause mortality. The secondary outcomes included improvements in functional independence, neurological impairment, activities of daily living, and reduction in hematoma expansion (HE). Fixed-effects or random-effects model were performed for pooled data where eligible. A total of 9 RCTs that initially enrolled 3,124 patients were included. There were no significant differences observed concerning all-cause mortality (RR, 1.03; 95% CI [0.89-1.18]), hematoma expansion (RR, 0.90; 95% CI [0.80-1.00]), improvement of functional independence (RR, 1.02; 95% CI [0.92-1.12], neurological impairment (MD, -0.88 [95% CI, -2.22-0.45]), or activities in daily living (MD, -0.83 [95% CI, -29.25-12.59]). The pooled data indicated that TXA for ICH was associated with a decrease in hematoma volume from baseline (MD, -1.74; 95% CI [-2.47 to -1.02]). No significant difference in adverse events was observed between the TXA group and the control group. In summary, TXA does not affect all-cause mortality, functional outcomes, or neurological impairment, nor does it reduce HE, despite reducing hematoma volulume. TXA use for ICH requires careful clinical consideration.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC3501104, 2018YFC1705001)
- National Natural Science Foundation of China (82104822)
- Young Elite Scientists Sponsorship Program by CACM (No. CACM-(2022-QNRC2-B06))
- Funding for Clinical Research at High-Level Traditional Chinese Medicine Hospitals in China Central (DZMG-ZJXY-23011)
- Funding for Clinical Research at High-Level Traditional Chinese Medicine Hospitals in China Central (DZMG-QNGG0005)
This publication has 38 references indexed in Scilit:
- Tranexamic Acid for Spontaneous Intracerebral Hemorrhage: A Randomized Controlled Pilot Trial (ISRCTN50867461)Journal of Stroke and Cerebrovascular Diseases, 2014
- GRADE guidelines: 8. Rating the quality of evidence—indirectnessJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 5. Rating the quality of evidence—publication biasJournal of Clinical Epidemiology, 2011
- GRADE guidelines 6. Rating the quality of evidence—imprecisionJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 7. Rating the quality of evidence—inconsistencyJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)Journal of Clinical Epidemiology, 2011
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhageNeurology, 2006